Human choriocarcinoma cell lines (i.e., BeWo, JAR, and JEG-3), as well as isolated primary trophoblast and Hofbauer cells, were shown to be permissive to HIV-1 infection in vitro and to sustain a low level of virus replication [5, 7, 9, 11] . The mechanism of entry is controversial. HIV-1 may enter via a CD4-dependent mechanism, a coreceptor, or a DC-specific intracellular adhesion molecule-grabbing nonintegrin (DC-SIGN)-dependent but CD4-independent mechanism, by endocytosis; through contact between peripheral blood mononuclear cells and placental cells; or by a combination of several of these mechanism [7, 8, 11, 12] .
Cytokines involved in placental and fetal growth could also be important. Enhanced production of inflammatory cytokines by trophoblast cells has been reported in HIV-1-infected pregnant women [13, 14] , as has placental inflammation [15] . Inflammatory cytokines may cause damage to the placental barrier, allowing transfer of the virus [16] , and could stimulate viral replication [17] (like tumor necrosis factor [TNF] , which increases HIV-1 replication [18, 19] ), because they are potent inducers of nuclear factor-kB (NF-kB), which is required for HIV-1 long terminal repeat (LTR) transcription [20] .
Progesterone, a sex steroid hormone naturally produced in the ovary and placenta [21] , is essential for pregnancy to reach full term. Its concentration (normally in the range of 1-10 nmol/L) increases during pregnancy (up to 0.3 mmol/L) in humans and mice [22] , and it appears to have anti-inflammatory properties. It inhibits T lymphocyte proliferation and function, as well as synthesis of Th1-type cytokines [22, 23] , and favors the development of human Th2-type cells [24] . Progesterone also inhibits the expression of inducible nitric oxide synthase in activated macrophages [25] and natural killer cells [26] and inhibits cytotoxic T lymphocyte function [27] and TNF synthesis [28, 29] .
Despite the influence of progesterone on immune function and pregnancy, its influence on HIV-1 replication has been scarcely studied. We studied the effect of progesterone on HIV-1 replication in trophoblast cells and placental cell lines, as well as the cellular and molecular mechanisms involved. We found that progesterone inhibits HIV-1 replication in infected or transfected placental cells. Progesterone affects neither the expression of chemokine receptors nor LTR transcription; rather, it inhibits HIV-1-induced TNF production, which is required, in an autocrine fashion, for HIV-1 replication in those cells.
MATERIALS AND METHODS

Isolation and culture of primary and trophoblastic cell lines.
Cytotrophoblasts were purified from normal full-term human placentas, after vaginal delivery. Several cotyledons were minced and digested in a calcium-and magnesium-free Hanks' (CMF Hanks') solution layered over fetal calf serum (FCS) centrifuged at 800g for 10 min and were resuspended in Dulbecco's MEM (DMEM) containing 25 mmol/L N-2-hydroxyethylpiperazine-N -2-ethane sulfonic acid and 25 mmol/L glucose. This suspension was layered over a preformed discontinuous Percoll gradient (Pharmacia) made up in CMF Hanks' solution (from 70% to 5% Percoll in 5% steps) centrifuged at 1200g for 20 min. Cells were collected at densities between 1.051 and 1.063, as determined by running parallel gradients (Pharmacia). Cytotrophoblasts were purified by immunomagnetic separation, by use of monoclonal antibodies against human HLA-ABC (class I) and HLA-DP, DQ, DR (class II). The purity was 197%, as confirmed by flow cytometric analysis with anticytokeratin antibodies (Dako AIS). The cells were cultured in DMEM-HG 20% FCS at a concentration of cells/ml. 6 10 To create polarized cells, we used Millicell filter inserts (Millipore) that were coated with 100 ug/mL of a basement membrane matrix (Matrigel; BD Biosciences) and placed within a well of a 24-well plate, as described elsewhere [30] . This system allows confluent cells to develop a polarized structure in which apical and basal domains are segregated and tight junctional complexes are formed.
Transformed trophoblastic cell lines JAR (ATCC HTB 144) [31] and JEG-3 (ATCC HTB 36) [32] were routinely grown in 10% FCS RPMI 1640 at 37ЊC in a humidified atmosphere of 5% CO 2 . Every 3 days, the cells were trypsinized and plated according to the experiment being performed.
HIV-1 infection of placental cells. The established viral strain HIV-1 NL4.3 and primary isolates from HIV-1-infected pregnant women (i.e., HIV-1 2069I [macrophage-tropic, R5] and HIV-1 1498I [lymphotropic, X4]) were used. The virus was added to individual cultures (MOI, 0.1 or 1) and was maintained at 37ЊC for 4 h. Cultures were extensively washed (between 10 and 20 times) with warm RPMI 1640, to remove all free virus. In some experiments, single cells were transfected with plasmid pNL4.3 encoding for the entire HIV-1 NL4.3 sequence and were stimulated with the indicated stimuli. At various times after infection, virus titer was quantified in the supernatant by p24 antigen production (Innotest HIV Antigen mAb; Innogenetics) or by the quantification of HIV RNA (i.e., the viral load) (Amplicor-HIV Monitor test; Roche). Peripheral blood mononuclear cells (PBMCs) were isolated from blood by Ficoll-Paque (Pharmacia) density gradient centrifugation and were infected by HIV-1 as described elsewhere [18] .
Flow cytometry. Cell surface expression of CCR5 and CXCR4 was evaluated by flow cytometry. Placental cells were recovered by treatment of the monolayers with 0.02% EDTAcontaining RPMI 1640 medium and were incubated with either fluorescein isothiocyanate anti-CXCR-4 or phycoerythrin anti-CCR5 (clone 12G5 and CTC5, respectively; R&D Systems) monoclonal antibodies or with irrelevant fluorescein isothiocyanate or phycoerythrin labeled as negative controls, at 4ЊC for 30 min. Surface fluorescence was determined using a FAC- Scan cytometer (Becton-Dickinson). A minimum of 10,000 cells/point was analyzed.
TNF mRNA detection. mRNA from placental cells was 5 10 isolated with oligo (dT)-coated magnetic beads. DNA amplification was performed using 5 mL of cDNA. Primers used for TNF amplification were as follows: sense 5 -GAGTGACAAGC-CTGTAGCCCATGTTGTAGCA-3 and antisense 5 -GCAAT-GATCCCAAAGTAGACCTGCCCAGACT-3 (obtained from Clontech Laboratories).
Real-time polymerase chain reaction (PCR) using 200 ng of total RNA was performed using a Roche Light Cycler PCR instrument and a Light-Cycler reverse-transcription PCR (RT-PCR) kit (Roche Perkin-Elmer). The standard used to make the control curve was the commercial plasmid pCRTM II (Invitrogen) into which a fragment of the TNF gene was inserted. The number of molecules of the plasmid was quantified by measuring the quantity of DNA in a spectrum photometer. Because the molecular weight of the standard (plasmid plus sequences of TNF) was known, the exact number of molecules could be extrapolated.
Transcription assays. The reporter pLTRWT-luc expression plasmid was a gift from J. L. Virelizier [33] . It carries the
U3
+ R of the LTR of the HIV-1 LAI strain of HIV-1 from nt Ϫ644 to 78+. The reporter pNF-kB-luc expression vector contains 3 tandem copies of the NF-kB site of the conalbumin promoter driving the luciferase reporter gene [34] . Human TNF promoter construct from nt Ϫ1311 (pTNFluc) coupling to luciferase has been described elsewhere [35] and was a gift from Dr. K. Rhoades.
For transfection assays, uninfected single trophoblast cells and JAR and JEG-3 cell lines were cultured in 12-well plates at cells/well, in a free FCS medium (Opti-Men; Life- 
RESULTS
Inhibition of HIV-1 replication in placental trophoblasts by progesterone.
We and other investigators have previously reported that placental cells can be infected by HIV-1 [5, 7, 9, 11] . However, the role of progesterone in HIV-1 infectivity has not been addressed. To address this, we treated placental cells with progesterone, with the lowest concentration used (10 ng/ mL) similar to levels found in the serum of nonpregnant women, and with the highest concentration used (3 mg/mL) the same as that noted at the placental interface [22] . Trophoblasts were infected with HIV-1 NL4.3 and were cultured over 3 days in the absence or presence of progesterone, and production of RNA-HIV-1 was quantified in the culture supernatants. We detected proviral DNA by use of nested PCR (not shown) [8] . HIV-1 replication was detected by quantification of the HIV-1 RNA load (figure 1A). The released viral particles were infectious. Progesterone significantly reduced replication in a dose-dependent manner, with the greatest effect occurring with the use of a concentration of 3 mg/mL.
As a control, we tested progesterone on T cell blasts that were infected with HIV-1 NL4.3 and were cultured over 3 days in the absence and presence of progesterone, and we then quantified the viral load. As expected, T cell blasts show much higher viral replication than do placental cells. Only the high dose of progesterone produced a statistically significant reduction (figure 1B) . Similar results were obtained with primary viral isolates HIV-1 2069I (macrophage-tropic, R5) and HIV-1 1498I (lymphotropic, X4) (not shown). This effect of progesterone was not the result of a toxic effect in placental cells, because it does not affect cell viability at that concentration. Moreover, progesterone does not affect cell proliferation or alter the cell cycle (data not shown).
Next, we tested whether the effect of progesterone takes place with polarized trophoblast to more closely parallel in vivo conditions. For this, we used polarized cells in Millicell filter inserts coated with Matrigel and added to the apical surface of the cells. As shown in figure 1C , HIV somewhat more efficiently inhibited polarized JEG-3 cells, but progesterone also inhibited HIV infection.
Although direct infection with HIV-1 has been reported, the virus may enter trophoblasts in a receptor-independent mechanism via cell-to-cell contact or through endocytosis [6] [7] [8] . To mimic cells infected in this way, we transfected single primary trophoblast cultures and single JAR and JEG-3 cell lines with the pNL4.3 provirus [36] . We found a time-and dose-dependent inhibition of the viral replication in all transfected cells (figure 2), indicating that progesterone could affect viral replication regardless of the mechanism of viral entry. Moreover, the inhibitory effect of progesterone was more pronounced in primary trophoblasts than in cell lines.
Chemokine receptor expression in placental trophoblasts not inhibited by progesterone. Some reports have suggested that HIV-1 infects placental cells via a coreceptor-dependent and CD4-independent mechanism [37] , and up-regulation of CCR5 in the placenta has been associated with vertical transmission [38] . Moreover, progesterone inhibits CXCR4 and CCR5 expression in PBMCs, and this correlates with reduced susceptibility to HIV-1 infection [39] . As previously shown elsewhere [8] , the trophoblastic JAR cell line expresses low levels of CXCR4 and somewhat higher levels of CCR5, but progesterone did not significantly inhibit their expression ( figure 3) . Similar results were found in primary trophoblast cells (not shown). In contrast, progesterone decreased CXCR4 expression in T lymphocytes (data not shown), in agreement with the findings of previous reports [39] .
No effect of progesterone on LTR transcription. The aforementioned results suggested that progesterone affects postentry steps. To test the effect of progesterone on viral transcription, we transfected single JAR cells with HIV-1-LTR-luc reporter plasmid. As shown in figure 4A , progesterone did not inhibit basal LTR transcription in any of the transfected single trophoblastic cell lines. Even though TNF was able to up-regulate LTR-driven transcription, progesterone did not inhibit this enhancing effect (figure 4B). LTR transcription is dependent on NF-kB [20] , and progesterone had no effect on basal transcription of a kB-dependent luciferase reporter gene. On the other hand, TNF strongly induced this reporter, but this effect was not altered by progesterone ( figure 4C) .
Effect of TNF on HIV-1 replication in placental cells. Recent results indicate that HIV-1 replication was strongly enhanced by TNF in placental cells and that progesterone can inhibit TNF synthesis by macrophages [28, 29] . Therefore, an attractive hypothesis was that HIV-1 induced TNF, which, in turn, increased HIV-1 replication, and that progesterone is able to break this cycle by inhibiting TNF synthesis. We first addressed whether "in vitro" HIV-1 infection of placental trophoblasts and placental cell lines could induce TNF expression. TNF secretion by trophoblast cells decreased by progesterone. To address the effect of progesterone on TNF, we performed quantitative PCR. As shown in figure 7A , HIV-1 infection induces TNF mRNA in a time-dependent manner. A significant amount of TNF mRNA was detected 4 h after infection, and the amount increased up to 72 h. Progesterone at a concentration of only 3 mg/mL reduced this increase on the order of 2-3 logs, depending on the experiment and the time measured after infection (figure 7A). Interestingly, exogenous TNF strongly increased its own production (5-10-fold), and neutralizing anti-TNF antibodies reduced it by 70%.
The aforementioned results suggested that HIV-1 triggers TNF transcription. Therefore, we transfected single JAR cells with a full TNF-promoter construct [35] and cultured them in the presence of inactivated HIV-1. This was enough to induce a strong TNF promoter-dependent transcription ( figure 7B ). This effect can be mimicked by simply culturing the cells with HIV-1 gp120. Progesterone inhibited virus or gp120-mediated TNF transcription, especially at a concentration of 3 mg/mL. The effect of TNF on the induction of its own promoter was mostly unaffected by progesterone, indicating that the effect of progesterone on TNF induction was specific for virus-induced TNF transcription.
DISCUSSION
Transplacental transmission of HIV-1 is the result of a complex interplay of maternal, fetal, and viral factors. Progesterone is a hormone essential for the maintenance of pregnancy [21, 40] . However, its influence on HIV-1 replication, especially in the placental cells, had not been studied. In the present study, we showed that progesterone limits HIV-1 replication in primary trophoblasts and cell lines. Progesterone does not inhibit HIV replication by acting on NF-kB or LTR-dependent transcription but, likely, through an indirect mechanism involving the inhibition of TNF synthesis in infected placental cells. This is suggested by the fact that HIV-1 infection induces TNF in placental cells and that progesterone inhibits this induction. Neutralization of endogenous TNF by anti-TNF antibodies has an effect similar to that of progesterone on viral replication. Of interest, inactivated virus or gp120 is sufficient to induce TNF mRNA transcription in placental cells, effects that are blocked by progesterone.
Some reports have suggested that HIV-1 infects placental cells via a coreceptor-dependent and CD4-independent mechanism [37] and that an up-regulation of CCR5 in the placenta has been associated with vertical transmission [38] . Progesterone inhibited CXCR4 and CCR5 expression on PBMCs, thereby reducing HIV-1 infectivity [39] . However, we found no significant alteration in coreceptor expression in placental cells by progesterone treatment administered at any dose tested, thus discarding this mechanism as an explanation of the anti-HIV-1 activity of progesterone in placental cells.
Because HIV-1 may enter by endocytosis or by cell-to-cell contact [6] [7] [8] , we tested the effect of progesterone on single placental cells transfected with an HIV-1 plasmid that mimics the effect of entering the cells through a receptor-independent entry [36] . Even in single cells transfected with the entire provirus, progesterone strongly inhibits HIV-1 replication, which is more pronounced in primary trophoblasts than in established cell lines. Previous studies have shown that the susceptibility of trophoblast cells to HIV-1 infection was enhanced by TNF. We found that replication of HIV-1 in placental cells, either by direct infection of cells or transfection of single cells with provirus, is strongly enhanced by the addition of TNF. To our knowledge, we show, for the first time, that neutralizing anti-TNF antibodies are able to significantly and severely reduce HIV-1 replication in infected cells, indicating an autocrine role of this cytokine in placental HIV-1 replication.
Inflammatory cytokines, such as TNF, have been more often produced both by the PBMCs and, in vivo, by the placental trophoblast cells of HIV-1-infected women [13, 15] . TNF levels may be a determining factor in the probability of vertical transmission. In this regard, a recent study indicates that some of the effects of zidovudine in preventing vertical transmission may be caused by decreasing TNF expression in the placenta [41] . TNF induced by HIV-1 infection, in turn, increases viral replication in placental cells that are infected either directly, through transfection (as in the present study), or through endocytosis [7] .
Our results suggest that virus released from the first rounds of infection could continuously stimulate TNF, which, in turn, induces virus release, thus perpetuating the infection. This TNF could act at various levels. First, it could activate viral replication in the same cells in which it is produced (as in the present study), and this increase in trophoblast cells increases the likelihood of new infections from the infected maternal PBMCs [7, 8] . These newly released virions could then infect underlying susceptible fetal cells, including Hofbauer cells [42] or PBMCs of the fetus. TNF would also contribute to placental damage and would favor the entry of either HIV-1 or the maternal infected cells through placental tissues from maternal to fetal blood [43] . Progesterone may act by breaking this cycle. Progesterone blocks TNF production in macrophages [28, 29] and placental cells (as in the present study) and diminishes HIV-1 replication in PBMCs [39] and placental cells. Thus, high progesterone levels during gestation could prevent vertical HIV-1 transmission by inhibiting TNF and viral replication in trophoblast cells and in PBMCs in contact with the placental interface. Preliminary results from our laboratory indicate that the progesterone level is higher in HIV-1-infected mothers who do not transmit HIV-1 than in HIV-1-infected mothers who do transmit HIV-1. On the contrary, progesterone treatment seems to enhance vaginal transmission of simian immunodeficiency virus in rhesus macaques, although this is likely the result of thinning of the vaginal barrier [44] .
Progesterone enhances IL-10 [45] , which is known to suppress TNF induction in some cell types [46] . In the presence of progesterone, activated human lymphocytes, especially g/d T cells, synthesize a 34-kDa molecule (progesterone-induced blocking factor [PGIF] ) that suppresses TNF production by NK cells [47] . We do not know whether the release of similar factor(s) has taken place in our system. However, we think that this is unlikely, because the effects of progesterone on TNF are observed from very early in the infection, which is not entirely compatible with the need for newly synthesized proteins, either IL-10 or PGIF. The mechanism by which progesterone affects HIV-1 or gp120-induced TNF transcription is not known and is currently under investigation. TNF transcription is dependent of NF-kB, although many different transcription factors may play a role, depending on the cell and the stimulus [48, 49] . A progesterone-mediated increase in IkB (a protein that blocks NF-kB) in macrophages [28, 29] or myometrial cells [50] and the eventual reduction in TNF mRNA have been reported. However, this hormone was unable to inhibit basal or TNFinduced activation of NF-kB in our trophoblast cells. This will fit with the fact that progesterone did not affect TNF-dependent LTR transcription, which is dependent on NF-kB activation. Progesterone does not affect TNF induction of its own promoter. Thus, it is likely that progesterone may affect transcription factors specifically induced by gp120.
